Establishment of a PDTT Xenograft Model of Gastric Carcinoma and Its Application in Personalized Therapeutic Regimen Selection

Hepatogastroenterology. Sep-Oct 2011;58(110-111):1814-22. doi: 10.5754/hge11136. Epub 2011 Jul 15.


Background/aims: Lack of appropriate tumor models that reliably predict response to anticancer agents remains a major deficiency in the clinical practice of personalized cancer therapy. The aim of our study was to establish a patient-derived tumor tissue (PDTT) xenograft model of gastric carcinoma for personalized cancer therapeutic regimen selection and testing of novel molecularly targeted agents.

Methodology: Patient-derived tumor tissue of primary gastric carcinoma was used to create the xenograft model. After 11 weeks, xenografts were harvested for serial transplantation. H&E staining, immunohistochemical staining and Western blotting were used to determine biological stability of the xenograft during serial transplantation compared with the original tumor tissue. Drug sensitivities of the xenograft to bevacizumab (Avastin), FP3 and cetuximab were evaluated.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Bevacizumab
  • Blotting, Western
  • Cetuximab
  • Humans
  • Male
  • Mice
  • Middle Aged
  • Precision Medicine*
  • Recombinant Fusion Proteins / pharmacology
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / therapy*
  • Xenograft Model Antitumor Assays


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • FP3 VEGF receptor Fc-fusion protein
  • Recombinant Fusion Proteins
  • Bevacizumab
  • Cetuximab